Evidence map›Paper›PMID 40563678›Full record

ArticleCancers2025

Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy.

Elisa Buzzatti, Giovangiacinto Paterno, Raffaele Palmieri, Fabiana Esposito, Lucia Cardillo, Kristian Taka, Lucrezia De Marchi, Marco Zomparelli, Kleda Zaganjori, Flavia Mallegni and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elisa BuzzattiHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.ORCID 0000-0002-3478-5083
Giovangiacinto PaternoUOSD Mieloproliferative, Policlinico Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-8944-0795
Raffaele PalmieriHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.ORCID 0000-0003-2855-8121
Fabiana EspositoHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.ORCID 0000-0002-7305-7222
Lucia CardilloHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.ORCID 0009-0001-5019-0020
Kristian TakaHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.
Lucrezia De MarchiHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.ORCID 0009-0009-3797-0741
Marco ZomparelliHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.
Kleda ZaganjoriHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.
Flavia MallegniHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.
Elisa MeddiHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.
Federico MorettiHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.ORCID 0000-0001-6730-5296
Ilaria CerroniHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.
Carmelo GurnariHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.ORCID 0000-0001-6829-5544
Luca MaurilloUOSD Mieloproliferative, Policlinico Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-7297-4988
Francesco BuccisanoHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.ORCID 0000-0003-4320-9253
Adriano VendittiHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.ORCID 0000-0002-0245-0553
Maria Ilaria Del PrincipeHematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) necessitates timely treatment, yet the impact of prolonged time to treatment (TTT) on clinical outcomes remains debated, especially its impact on achieving measurable residual disease (MRD) negativity, a powerful prognostic indicator in AML.

methodsThis retrospective study analyzed 196 adult AML patients treated with intensive chemotherapy, evaluating the effect of TTT on outcome measures and quality of response. TTT was categorized arbitrarily into <8, 8-14, and >14 days.

resultsResults showed a median TTT of 11 days. Median overall survival (OS) was 414 days, with no significant differences among TTT groups (

conclusionsThis study suggests that a treatment delay of up to 14 days does not negatively impact OS or MRD negativity. This timeframe potentially allows for thorough patient evaluation, including detailed genetic profiling and comorbidity assessment, facilitating a more personalized and optimized therapeutic strategy.

Indexed as

acute myeloid leukemiaintensive chemotherapymeasurable residual diseasetime to treatment

Identifiers

PMID40563678
PMCPMC12191022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.